Vivos Córas Máinliachta Oftalmach le Olcayto Guelec and David Geuder

Tha Vivos Córas Máinliachta Oftalmach le Olcayto Guelec and David Geuder na bhuannaiche air leth urramach anns an fharpais chliùitich 2026 Duais Òir A' Design Award ann an Roinn Farpais Dealbhadh Innealan agus Uidheamachd Meidigeach.

ÒrToradh Meidigeach· 2026

Vivos Córas Máinliachta Oftalmach

le Olcayto Guelec and David Geuder

Neach-ceannach: Geuder AG

Buannaiche Duais Òir A' Design Award ann an Roinn Toradh Meidigeach

56,783

Buannaiche Duais Dearbhaichte

Dearbhaich Inbhe na Duaise airson #182492

Seall aig A' Design Award Brath Naidheachd Suaicheantas Duaise

Dathan

An Dealbhadh

Mu dheidhinn Vivos Córas Máinliachta Oftalmach

Athshainíonn Vivos an stáisiún oibre máinliachta mar ardán a fhorbraíonn taobh le taobh le huaillmhian chliniciúil. Leathnaíonn trí chumraíocht, Core, Nova, agus Nova+, an cumas gan an córas a athsholáthar, an t-aon ailtireacht uasghrádaithe dá leithéid i máinliacht oftalmach. Léiríonn comhéadan aonair, a bailíochtaíodh ag 91.7 faoin gcéad de shástacht chéad úsáide gan aon oiliúint roimh ré, dearadh atá tógtha timpeall an mháinlia seachas timpeall an nós imeachta. Tugann naisc uirlisí soilsithe, ábhair mhionchoigeartaithe agus mionsonraí srianta láithreacht shocair fhéinmhuiníneach don ghléas, saor ón trup amhairc atá coitianta don chatagóir.

An Aithneachadh

Mu dheidhinn Duais Òir A' Design Award

Tha Vivos Córas Máinliachta Oftalmach air Duais Òir A' Design Award a bhuannachadh, aithneachadh anabarrach urramach a bheirear do dhealbhaidhean den chiad ìre, mìorbhaileach agus sònraichte. Tha buannaichean Òir nan cruthachaidhean anabarrach ùr-ghnàthach, làn lèirsinn agus drùidhteach a nochdas gèinidh, gliocas agus comas an luchd-dealbhaidh. Thathar an dùil gum bi Vivos Córas Máinliachta Oftalmach na innleachd a gheibh moladh mòr, a stèidhicheas gluasadan agus mòr-chuimhneachain a bheir luach nach fhacas riamh roimhe. Tha an dealbhadh seo a bhuannaich Duais Òir A' Design Award na phròiseact sònraichte, urramach a bhrosnaicheas crìochan ealain, saidheans, dealbhaidh agus teicneolais gu mòr. Bidh Vivos Córas Máinliachta Oftalmach a' cruthachadh faireachdainnean làidir miann, a' dùsgadh dealas, a' brosnachadh cruthachalachd agus a' glacadh sinn.

Air Cùl an Dealbhaidh

Pasgan Naidheachd

Creideasan, buill sgioba agus fiosrachadh teicnigeach a chuir an dealbhaiche ri chèile.

Feartan Sònraichte: Vivos is the only ophthalmic surgery system that grows with clinical needs. Core for cataract. Nova adds vitrectomy. Plus adds laser. One platform. One interface. One training investment. Independent usability validation confirmed 92 percent user satisfaction among first time users. Illuminated connection sockets were rated positively by all study participants. Premium materials and restrained detailing give the device a likeable presence without the visual noise typical of the category.
Tomhasan & Pacadh: Display: 24 inch capacitive touchscreen. Vitrectomy: up to 40000 cuts per min. Vacuum: up to 700 mmHg, highest in category. Phacoemulsification: 53 kHz piezoelectric. IOP: active real-time (VIVOS Balance). Endolaser: 532 nm. Illumination: SOLEA LED, 16.9M colours, 2 ports, Retina Protection Mode. CE pending, submitted Feb 2026. ISO 13485 2016.
Tagaichean: Ophthalmic Surgery System, Medical Device Design, Phacoemulsification, Vitrectomy, Modular Medical Platform, Surgical Ergonomics, Workflow Design, German Medical Engineering, Usability Validation, Premium Medical Aesthetics
Teicneòlas Cinneasachaidh: Medical-grade polycarbonate housing, antimicrobial surface coating rated for over 10,000 disinfection cycles. Piezoelectric phacoemulsification at 53 kHz with beveled-up probe geometry for optimised fluidics. Pneumatic vitrectomy probe up to 40,000 cuts/min. IEC 60601-1 compliant. Modular quick-change cassette - single or multi-patient - tool-free exchange. Compatible with older phaco handpieces, protecting prior investment. Individually assembled in Heidelberg. ISO 13485:2016, IEC 62366-1, IEC 60601-1, CE pending
Dùbhlan Dealbhaidh: The central challenge was integrating six surgical functions, historically distributed across two to three separate devices, into a single platform without increasing cognitive load. Internally, decades of segmented product architecture and a 75-year heritage required rethinking established engineering logic. Externally, MDR regulations, IEC 62366 1 usability standards and strict OR hygiene constraints limited design freedom. Maintaining identical UX across Core, Nova and Plus while ensuring durability for thousands of cleaning cycles demanded systemic redesign rather than incremental improvement.
Rannsachadh: Usability research was conducted. Objective: reduce cognitive load without limiting clinical capability. Methodology: iterative co-design workshops with surgeons, Geuder teams and engineering, followed by independent summative validation per IEC 62366-1. Data collection included usability testing and task-based evaluations. Participants: 13 first-time users at RWTH Aachen University, 2026. Results: 91.7% satisfaction, no unacceptable residual risks. Insights validated the workflow UI, surgeon profiles and illuminated sockets, contributing to greater efficiency, improved patient safety and long-term system adoption in clinical practice.
Brosnachadh: Ophthalmic surgery is precise. Why should its devices remain fragmented, complex and visually uninspiring. Anterior and posterior procedures require separate investments, training and ecosystems not because clinical need requires it but because no manufacturer redesigned the architecture around the surgeon. Geuder AG with seventy five years of ophthalmic expertise asked what if one platform could grow without hardware replacement. Validated by independent study and unique in its modular upgrade logic.
Faid a' Phròiseict: The project was developed in Heidelberg, Germany by Geuder AG. Development spanned multiple months with iterative design and engineering phases conducted in close collaboration with ophthalmic surgeons and operating room nursing staff. Summative usability validation was performed at RWTH Aachen University in early 2026. CE Mark application was submitted on 27 February 2026. Public market launch is scheduled for June 2026.
Sruth Obrachaidh: Before each procedure, the surgeon selects a personal profile, preloading preferred settings and pedal sensitivity. A three-column touchscreen maps each surgical step as a visual sequence. Colour-coded modules allow instant identification in a darkened theatre. Illuminated sockets guide instrument connection by touch. The foot pedal, with individually adjustable actuation force, controls fluid flow and laser hands-free. Eye pressure is monitored and adjusted in real time.
Buill na Sgioba: Collaboration between Geuder AG's Engineering, Quality Management, Regulatory Affairs, Product Management, Service, Application, Development, and Sales departments.
Creideasan Dhealbhan: Photography Geuder AG, 2026